Sandoz Launches New Global ‘Act4Biosmilars’ Initiative to Increase the Biosimilar Adoption Worldwide
Shots
- Sandoz launched ‘Act4Biosmilars’ to address health inequity & inequality globally along with increase patient's access to advanced therapies & adoption by 30% in over 30 countries by 2030
- The Steering Committee is developing an Action Plan to provide the roadmap and tools to improve the approvability, accessibility, acceptability, and affordability (4As) of biosimilars with a group of biosimilar experts & key stakeholders
- Act4Biosimilars.com lists the 12 goals that have been identified by Steering Committee to fulfill the mission under the 4As to ensure equitable pricing, involve patients in treatment decisions & streamline the biosimilar development
Ref: Globenewswire | Image: Sandoz
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
